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Selective prescribing of conventional antipsychotic medication (APM) to frailer patients is thought to have led to
overestimation of the association with mortality in pharmacoepidemiologic studies relying on claims data. The
authors assessed the validity of different analytic techniques to address such confounding. The cohort included
82,012 persons initiating APM use after admission to a nursing home in 45 states with 2001–2005 Medicaid/
Medicare data, linked to clinical data (Minimum Data Set) and institutional characteristics. The authors compared
the association between APM class and 180-day mortality with multivariate outcome modeling, propensity score
(PS) adjustment, and instrumental variables. The unadjusted risk difference (per 100 patients) of 10.6 (95%
confidence interval (CI): 9.4, 11.7) comparing use of conventional medication with atypical APM was reduced to
7.8 (95% CI: 6.6, 9.0) and 7.0 (95% CI: 5.8, 8.2) after PS adjustment and high-dimensional PS (hdPS) adjustment,
respectively. Results were similar in analyses limited to claims-based Medicaid /Medicare variables (risk difference
¼ 8.2 for PS, 7.1 for hdPS). Instrumental-variable estimates were imprecise (risk difference ¼ 8.8, 95% CI: 1.3,
19.0) because of the weak instrument. These results suggest that residual confounding has a relatively small
impact on the effect estimate and that hdPS methods based on claims alone provide estimates at least as good as
those from conventional analyses using claims enriched with clinical information.
antipsychotic agents; confounding factors (epidemiology); dementia; mortality; nursing homes; pharmacoepidemiology
Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; hdPS, high-dimensional propensity score;
IV, instrumental variable; MDS, Minimum Data Set; OSCAR, Online Survey, Certification and Reporting; PS, propensity score.
Dementia is highly prevalent in older populations, and the
number of people with dementia is expected to nearly double
worldwide by the year 2020 (1, 2), making clinical manage-
ment of these patients an important public health concern.
Behavioral disturbances—such as psychosis, agitation, ag-
gression, irritability, disinhibition, and wandering—are often
among the most distressing aspects of dementia and are the
primary reason older adults with dementia enter nursing homes
(3). Between one-fifth and one-third of all nursing home
patients in North America are currently being given antipsy-
chotic agents (4–8), mostly for the treatment of dementia-
related behavioral disturbances, despite the fact that these
medications are not approved by the Food and Drug Admin-
istration (FDA) for this indication. Over time, use has shifted
from older, conventional agents to the newer atypical agents
(9). However, neither class of antipsychotic medication has
well-established efficacy in this older, vulnerable population,
and recent data have raised serious safety concerns regard-
ing both types of medications (10–14).
In 2005, the FDA issued an advisory warning that atypical
antipsychotic medications were associated with a 60%–70%
increased risk of death in comparison with placebo in 17
short-term randomized controlled trials carried out among
older dementia patients (15), and ‘‘black-box’’ warnings were
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added to the labels of all atypical agents. Most of the deaths
appeared to be cardiovascular or infectious in nature (10). In
June 2008, the FDA issued a similar black-box warning for
conventional antipsychotic agents after judging the overall
weight of the evidence, which included nonrandomized stud-
ies based on health-care utilization databases (11–14).
Although these nonrandomized studies (12–14) estimated
a greater risk of death with use of conventional antipsychotic
agents than with use of atypical antipsychotic agents, the
FDA judged that ‘‘the methodological limitations in these
studies preclude any conclusion that conventional antipsy-
chotics have a greater risk of death with use than atypical
antipsychotics’’ (11). Indeed, despite their unique strengths
for comparative safety research (16, 17), pharmacoepidemio-
logic studies based on administrative claims data have a
number of inherent limitations, the most important of which
is incomplete information on potential predictors of study
outcomes that might also lead to selective prescribing, re-
sulting in biased estimates of effect. It has been argued that
such factors (e.g., limitations in cognitive and physical func-
tioning) may have led to selective prescribing of conventional
antipsychotics to patients who were closer to death (18),
which would have resulted in overestimation of the associ-
ation between use of conventional antipsychotic medication
and short-term mortality (19). Because the FDA advisories
do not acknowledge the increased risk associated with con-
ventional antipsychotics as compared with atypical antipsy-
chotics because of concerns about residual confounding,
clinicians and policy-makers are left with inadequate guid-
ance on the treatment decisions they face on a daily basis for
a growing segment of the population.
In the current study, we sought to address whether the mor-
tality risks are indeed equal for both classes of antipsychotic
medication in older patients with dementia-related behavioral
problems, so that we could understand whether one class has
a safety advantage that merits preferential prescribing. We
used a range of analytic approaches and data sources to mit-
igate residual confounding bias. Aside from addressing the
specific clinical question at hand, we aimed to provide re-
searchers with some guidance on the merits of these different
approaches—specifically the merits of high-dimensional pro-
pensity score (hdPS) adjustment versus standard propensity
score (PS) adjustment with enriched data sources—to enhance
causal interpretation of the safety of other medications.
MATERIALS AND METHODS
Data source
The study cohort was drawn from a merged data set con-
sisting of Medicaid and Medicare claims, the Minimum Data
Set (MDS), and the Online Survey, Certification and Report-
ing (OSCAR) data set in 45 US states (all states except
Arizona, Delaware, Nevada, Oregon, and Rhode Island) for
the years 2001–2005. The MDS is a federally mandated health
assessment tool used in US nursing homes that captures
information on physical, psychological, and psychosocial
functioning, active clinical diagnoses, health conditions,
treatments, and services. Assessments are required upon ad-
mission, when a significant change in clinical status occurs,
and then periodically within specific guidelines (typically
quarterly). OSCAR is a compilation of data collected during
the inspection surveys conducted at nursing facilities to cer-
tify them for participation in the Medicare and Medicaid
programs. Inspections occur at least once during a 15-month
period. The OSCAR database includes information on nurs-
ing home operational characteristics and aggregate resident
characteristics.
Study population
Our cohort consisted of all patients aged 65 years who
were dually eligible for Medicaid and Medicare and initiated
treatment with antipsychotic medication after admission to
a nursing home. Patients who had filled a prescription for
antipsychotic medication during the 6 months before the
first antipsychotic medication prescription filled in the nurs-
ing home (prevalent users) were excluded, as were patients
with a preexisting diagnosis of cancer, schizophrenia, or bi-
polar disorder, since these patients were unlikely to receive
antipsychotic medication for age-related behavioral distur-
bances. The cohort was restricted to patients who had had an
MDS assessment in the 3 months before treatment initiation,
to ensure that recent information on health status was used,
and to patients residing in nursing homes that contributed
more than 5 patients during the study period, permitting more
accurate estimation of the nursing homes’ true prescribing
preference for use in the instrumental-variable (IV) approach.
Antipsychotic medications
The atypical antipsychotic agents studied included risper-
idone, olanzapine, quetiapine, aripiprazole, ziprasidone, and
clozapine. Other antipsychotic medications studied were
considered to be conventional agents, including haloperidol,
thioridazine, chlorpromazine, perphenazine, and fluphenazine.
The first new prescription filled for an antipsychotic agent
following nursing home admission determined the treatment
group into which a patient was classified: conventional or
atypical. Patients who filled a prescription for both types of
agents on the same day were excluded.
Outcome and potential confounders
The study outcome was death from any cause within
180 days of treatment initiation, as recorded in the Social
Security Death Master File (20). A 180-day follow-up period
was selected for comparability with existing studies (12–14).
Sociodemographic characteristics included age, sex, race,
education, and geographic region (state). Clinical characteris-
tics were determined on the basis of medication use, the most
recent MDS assessment before treatment initiation, and
International Classification of Diseases, Ninth Revision,
diagnostic and procedure codes recorded in claims for hos-
pitalizations and physician visits in the 6 months before
treatment initiation. Variables considered included psychi-
atric morbidity, cardiovascular morbidity, cerebrovascular
disease, Parkinson’s disease, epilepsy, diabetes, obesity, func-
tional impairment, and Charlson comorbidity index (21). The
use of health-care services that were potentially predictive
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of risk of death in the short term was also assessed (i.e.,
number of days hospitalized and number of distinct prescrip-
tion drugs used, excluding antipsychotic medications) (22).
Data on nursing home characteristics that may be correlated
with processes of care and thus risk of death were obtained
from OSCAR. These included variables such as number of
beds in the facility, occupancy rate, availability of Alzheimer’s
and other special care units, staffing levels, type of ownership
(e.g., for-profit), proportion of residents whose care was paid
for by Medicare/Medicaid, and variables related to resident
characteristics and quality indicators (e.g., proportion of res-
idents bed-bound, proportion with pressure sores, proportion
on psychoactive medication, number of deficiencies). A com-
plete list of all patient- and facility-level covariates considered
is included in Web Table 1 (http://aje.oxfordjournals.org/).
Data analysis
We performed 4 types of analyses representing increasing
levels of confounding adjustment: traditional multivariable
outcome modeling, PS analysis, hdPS analysis, and IVestima-
tion. For consistency with the IVapproach, primary analyses
implemented a first-exposure-carried-forward approach with-
out censoring (‘‘initially treated,’’ similar to intention-to-treat
analyses) and focused on comparisons of absolute risk.
Multivariate outcome modeling. Since none of the cova-
riates individually met the 5% change-in-effect-estimate crite-
rion we had postulated for selection of potentially confounding
variables for adjustment in the multivariate outcome model
(23), we forced selected case-mix variables into the model.
The selection of variables was informed by prior work in
this field, including the studies that formed the basis for the
FDA black-box warning (12, 14, 24).
PS and hdPS analyses. PSs at treatment initiation were
derived from predicted probabilities estimated in logistic
regression models of the use of conventional antipsychotic
medication versus atypical antipsychotic medication. To eval-
uate the added value of clinical and facility-level informa-
tion for confounding control, we fitted 4 different PS models
based on 1) Medicare and Medicaid claims only, 2) claims
and clinical (MDS) information, 3) claims and facility-level
(OSCAR) information, and 4) claims, clinical, and facility-
level information. The PS models included all variables spec-
ified as factors that might confound the causal drug-outcome
association based on our contextual knowledge of the study
question, as well as variables related to the outcome but not
related (or only weakly related) to the exposure (the specific
variables are listed in Web Table 1) (25). To assess the value
of the PS models for confounding control, the balance of
important risk factors for death between users of conven-
tional and atypical antipsychotic medication was checked
within deciles of the estimated PS (26, 27). We truncated
2.5% of the patients on either extreme of the PS distribution
and adjusted the outcome model for PS decile (28). Alter-
natively, we matched 1:1 on the PS using a greedy match
algorithm (29).
Similar analyses were conducted using the hdPS (30).
A limitation of standard approaches to confounding adjustment
which hdPSs attempt to overcome is their reliance on the in-
vestigator’s being able to specify all factors that may confound
a causal drug-outcome association. The hdPS algorithm eval-
uates thousands of diagnoses, procedures, and pharmacy claim
codes, as well as clinical (MDS) and facility (OSCAR)
characteristics (referred to as data dimensions), to identify
and prioritize those covariates that serve as proxies for un-
measured confounders. Specifically, the 200 most prevalent
codes in each data dimension are prioritized by calculating
for each covariate the possible amount of confounding it could
adjust in a multiplicative model given a binary exposure and
outcome, after adjustment for demographic covariates. These
covariates are then sorted in descending order of confounding
potential, and the top 500 empirical covariates are selected.
These empirically identified confounders are combined with
investigator-identified covariates (i.e., sociodemographic var-
iables and general indicators of comorbidity) to improve con-
founding adjustment. We also conducted secondary PS- and
hdPS-adjusted analyses with follow-up censored at the time
of treatment discontinuation or treatment switch, allowing
for a 30-day grace period (‘‘as-treated’’).
IV estimation. When different nursing homes use the two
types of antipsychotic medication at sharply disparate rates,
the choice is evidently influenced by factors that are indepen-
dent of patient characteristics, and it is possible to use the
nursing home’s preferred treatment as a substitute for the
actual exposure (i.e., as an IV) in analyses. We classified nurs-
ing homes that prescribed conventional antipsychotic agents
to at least 1 in every 3 patients as homes that preferred con-
ventional antipsychotic agents and nursing homes that pre-
scribed conventional antipsychotic agents to none of their
patients as those that did not prefer this type of medication.
Patients admitted to all other nursing homes (i.e., 0% <
cumulative proportion < 33%) were excluded from the anal-
ysis. To avoid introducing an artificial correlation between
this cumulative proportion and a given patient’s prescription,
we calculated a separate proportion for each patient using all
other patients admitted to that nursing home.
Using this preference or lack thereof as an IV (IV1), we
computed differences in the risk of 180-day mortality be-
tween the conventional antipsychotic medication group and
the atypical antipsychotic medication group, using the clas-
sic approach to IVestimation motivated from a causal theory
framework—that is, a 2-stage linear regression with and
without adjustment for measured covariates (31). We also
conducted an analysis in which nursing home prescribing
preference was determined by the treatment decision made
for the patient most recently admitted (IV2) (32).
To assess instrument strength, we computed the square of
the partial correlation between the instrument and treatment,
conditional on other covariates in the model. This partial R2
can be interpreted as the proportion of the variance explained
by the addition of the IV to the model. We measured change
in imbalance for measured covariates, comparing the pop-
ulation stratified by the treatment with the population stratified
by the IV. We used the percentage change in Mahalanobis
distance (33) as a summary measure of change in covariate
balance between exposure groups.
Finally, we conducted a sensitivity analysis to identify the
strength of the residual confounding that would be neces-
sary to fully explain the drug-outcome association estimated
using these different methods of adjustment (34).
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Table 1. Selected Characteristics of the Study Population and Nursing Homes According to Type of Antipsychotic Medication Used and Instrumental-Variable Status, United States,
2001–2005a
Type of APM Differenceb, by IV Status
Conventional (n 5 7,252) Atypical (n 5 74,760) Differencec IV1
d IV2
e
Mean No. % Mean No. % Mean No. % Mean No. % Mean No. %
Patient characteristics
IV status (no. of patients)
Conventional APM 3,462 6,631
Atypical APM 32,691 68,092
Male sex 32.1 24.7 7.5 2.1 0.5
Age, years 82.7 82.8 0.1 0.1 0.2
Race
Black 16.1 13.0 3.1 3.9 1.2
White 76.0 79.7 3.8 5.1 1.9
Other 6.6 5.7 0.8 1.4 0.8
Unknown 1.4 1.6 0.2 0.2 0.1
Calendar year
2001f 7.6 5.4 2.2 1.0 0.6
2002 18.4 18.2 0.1 1.1 2.1
2003 22.7 24.7 2.0 0.0 0.9
2004 24.0 26.8 2.8 1.2 2.4
2005 27.4 24.8 2.6 0.9 0.6
Cardiovascular morbidity
Myocardial infarction 8.9 7.3 1.5 0.2 0.0
Cardiac arrhythmia 29.4 26.8 2.6 0.2 0.1
Ischemic heart disease 6.3 5.6 0.7 0.0 0.2
Hypertension 70.0 69.2 0.8 1.3 0.6
Congestive heart failure 40.8 34.9 5.8 2.4 1.1
Coronary artery disease 34.8 32.3 2.5 0.7 0.1
Other cardiovascular disease 42.1 37.9 4.2 0.1 1.1
Hospitalization for circulatory system disorder 18.8 16.2 2.7 1.5 0.4
Cerebrovascular disease 33.8 32.1 1.6 2.1 1.2
Parkinson’s disease 4.7 6.0 1.2 0.1 0.5
Psychiatric morbidity
Dementia 70.9 76.2 5.3 4.2 1.1
Depression 48.4 54.7 6.4 3.8 2.5
Anxiety 18.0 18.7 0.6 0.1 0.1
Delirium 53.3 53.6 0.3 0.6 1.6
Psychotic disorder 12.9 14.3 1.4 1.4 0.7
Delusions 2.5 3.4 0.9 0.1 0.2
Cognitive impairment
Cognitively intact or mild impairment 0.5 0.6 0.1 0.1 0.0
Moderate impairment 14.1 14.2 0.1 0.7 0.1
Moderate to severe impairment 55.1 56.6 1.5 0.7 0.5













































Independent or limited impairment 35.6 38.0 2.4 1.8 0.6
Dependent or extensive impairment 58.2 57.1 1.1 1.2 0.6
Total dependence 6.2 4.9 1.3 0.6 0.1
Verbally and/or physically abusive behavior 12.5 13.4 0.9 0.6 0.2
Nonaggressive behavioral problems 24.0 25.5 1.5 0.2 0.5
Medication history
Antidepressant medication 57.8 65.3 7.5 3.4 1.8
Hypnotic medication 48.7 44.2 4.4 4.6 1.4
Other psychotropic medication 10.8 12.4 1.6 1.1 1.3
Dementia medication 24.2 32.1 7.9 4.2 1.9
Charlson comorbidity index
0 4.2 4.0 0.2 0.7 0.1
1 13.4 14.5 1.1 0.4 0.4
2 18.5 20.8 2.3 1.3 0.4
3 18.1 19.4 1.3 0.4 0.1
4 15.2 15.1 0.1 0.1 0.1
5 10.8 10.6 0.2 0.1 0.7
>5 19.9 15.6 4.3 0.5 0.3
No. of different prescription drugs received 15.6 14.3 1.29 0.52 0.18
Nursing home characteristics
No. of nursing homes (out of 7,867) prescribing
specified type of APM
4,139 7,866
Team-based physician care 25.2 29.0 3.9 10.7 3.9
No physician on staff g 15.6 14.0 1.6 4.3 1.3
Mental health staff available 50.7 54.8 4.2 13.6 4.1
% of patients with facility-acquired bed sores 0.036 0.036 0.00 0.00 0.00
% of patients on psychoactive medication 0.61 0.62 0.01 0.03 0.01
Total no. of documented deficiencies at facility 7.1 6.8 0.25 0.34 0.29
Summary change in imbalanceh 34.8 42.5
Abbreviations: APM, antipsychotic medication; IV, instrumental variable.
a The study cohort was drawn from a merged data set consisting of Medicaid and Medicare claims, the Minimum Data Set, and the Online Survey, Certification and Reporting (OSCAR) data set in 45 US states (all
states except Arizona, Delaware, Nevada, Oregon, and Rhode Island) for the years 2001–2005.
b Difference in prevalence between treatment groups after stratification by the IV. Smaller numbers indicate greater balance. Differences greater than 3% are shown in italic type.
c Difference in prevalence between actual treatment groups. Smaller numbers indicate greater balance. Differences greater than 3% are shown in italic type.
d Conventional APMs were preferred if the nursing home used conventional APMs in at least one-third of patients; atypical APMs were preferred if the nursing home never used conventional APMs (45,859 patients were
dropped from the analysis because they were admitted to nursing homes that prescribed conventional APMs to some patients but fewer than 33% of the patients admitted).
e Treatment given to previously admitted patient in a given nursing home (7,289 patients were dropped from the analysis because they were the first patient admitted to a given nursing home during the study period).
f The first 6 months of 2001 were used to determine study eligibility and define baseline covariates. Therefore, no patients could enter the cohort during this time, which explains the smaller proportion of APM users in
calendar year 2001.
g No physician on staff who supervises the care of residents when the attending physician is unavailable.
h Calculated by subtracting the Mahalanobis distance from the data stratified by treatment from the data stratified by the IV and then dividing by the distance as stratified by treatment. Positive numbers represent























































Because patient-level observations were clustered within
nursing homes, robust calculations of standard errors of
the regression parameters were performed using generalized
estimating equations.
RESULTS
A total of 82,012 older nursing home patients were included
in our cohort; of these, 7,252 (8.8%) were prescribed a con-
ventional antipsychotic medication and 74,760 (91.2%) were
prescribed an atypical formulation. The proportion of pa-
tients receiving a conventional agent decreased from 12.0%
in 2001 to 8.0% in 2004 but increased again to 9.7% in 2005,
the year in which the FDA issued warnings of excess mor-
tality associated with atypical antipsychotic agents. Subjects
in the conventional drug group were more likely to be male
and nonwhite than those in the atypical drug group (Table 1).
Compared with the atypical drug users, the conventional
drug users were more likely to have cardiovascular disease
(especially congestive heart failure and other cardiovascular
disease) and less likely to have psychiatric comorbidity (es-
pecially dementia and depression). Both groups were rela-
tively comparable in terms of the severity of cognitive and
functional impairment and the presence of diagnosed behav-
ioral problems based on MDS data. Users of conventional
antipsychotic medication had lower rates of antidepressant
and dementia medication use but higher rates of hypnotic
medication use. They also were more likely to have a Charlson
comorbidity index greater than 5. Conventional drug users
were more likely than atypical drug users to reside in a nurs-
ing home without mental health staff and without team-based
care (Table 1).
In the first 180 days of use, 30% of patients who began
using conventional antipsychotic agents died, as compared
with 20% of those who began using atypical agents (Table 2).
The mean survival times for initiators of conventional and
atypical antipsychotics were 30 days and 63 days, respectively.
The excess of 10.56 deaths per 100 persons (95% confidence
interval (CI): 9.42, 11.70) in conventional antipsychotic med-
ication users as compared with atypical antipsychotic med-
ication users was reduced to 8.29 per 100 persons (95% CI:
7.34, 9.24) after adjustment for the claims-based potential
confounders listed in Table 3.
Adjustment for a wide range of sociodemographic and
claims-based covariates through the use of PS deciles resulted
in a risk difference of 8.17 per 100 persons (95% CI: 7.00, 9.34)
Table 2. Mortality Among Nursing Home Residents Within 180 Days After Initiation of Antipsychotic Medication Use, United States, 2001–2005
Variable
Type of Antipsychotic
Medication Difference 95% CI Ratio 95% CI
Conventional Atypical
No. of persons 7,252 74,760
No. of person-years 2,872.8 32,836.4
No. of deaths 2,184 14,618
Risk of death in first 180 days (per 100 persons) 30.12 19.55 10.56 9.42, 11.70 1.54 1.48, 1.60
Rate of death per 100 person-yearsa 76.02 44.52 31.47 27.90, 35.04 1.71 1.63, 1.79
Abbreviation: CI, confidence interval.
a Censoring at the time of death or 180 days, whichever came first.
Table 3. Risk of Death Among Nursing Home Residents Within 180 Days After Initiation of Antipsychotic Medication Use (Conventional vs.





95% CI Risk Ratio 95% CI
Adjusted for age and sex 10.27 9.14, 11.41 1.50 1.44, 1.56
Multivariable analysisa 8.29 7.34, 9.24 1.31 1.27, 1.36
Rate Difference
(per 100 Person-Years)b
95% CI Rate Ratiob 95% CI
Adjusted for age and sex 30.54 27.00, 34.07 1.67 1.59, 1.76
Multivariable analysisa 26.41 23.78, 29.04 1.54 1.46, 1.61
Abbreviation: CI, confidence interval.
a Adjusted for age, sex, race, calendar year, presence or absence of myocardial infarction, cardiac arrhythmias, hypertension, congestive heart
failure, coronary artery disease, other ischemic heart disease, other cardiovascular disorder, hospitalization for problems of the circulatory system,
cerebrovascular disease, Parkinson’s disease, diabetes, dementia, depression, anxiety, delirium, other psychotic disorders, prior use of antide-
pressants, hypnotics, and other psychotropic medications, dementia treatment, Charlson comorbidity index, and total number of medications used.
b Censoring at the time of death or 180 days, whichever came first.
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(Table 4). Addition of clinical information (MDS) and nurs-
ing home characteristics (OSCAR) to the PS did not mean-
ingfully change the effect estimate; the risk difference after
adjustment for all 3 categories of covariates was 7.79 per
100 persons (95% CI: 6.61, 8.96). Use of hdPS further re-
duced the risk difference to 7.07 per 100 persons (95% CI:
5.89, 8.24) based on claims data only and 7.00 per 100
persons (95% CI: 5.83, 8.17) based on all covariate cate-
gories (Figure 1). A similar pattern was observed with PS
matching (Table 4).
Secondary analyses using the ‘‘as-treated’’ approach yielded
no substantive changes relative to these ‘‘initially treated’’
analyses. For example, the unadjusted incidence rate ratio
of 2.36 (95% CI: 2.20, 2.54) was reduced to 1.99 (95% CI:
1.85, 2.14) after hdPS adjustment using claims, MDS, and
OSCAR information. The effect was strongest during the
first 40 days of treatment (hdPS-adjusted incidence rate
ratio ¼ 1.98, 95% CI: 1.82, 2.16); the incidence rate ratios
decreased to 1.59 (95% CI: 1.35, 1.87) and 1.38 (95% CI:
1.13, 1.68) after 40 –79 days and 80 –180 days of medication
use, respectively.
In the IVanalyses, use of conventional antipsychotic agents
continued to be associated with an increased risk of death
within 180 days in comparison with use of atypical formu-
lations. The adjusted risk differences were estimated at 8.84
per 100 persons (95% CI:1.28, 18.95) for IV1 (a low rate of
conventional medication prescription vs. a high rate) and
8.59 per 100 persons (95% CI: 8.97, 26.14) for IV2 (prior
patient), implying that for every 100 patients prescribed a
conventional drug instead of an atypical drug (i.e., the mar-
ginal patients whose treatment status can be affected by the
instrument), there would be 9 additional deaths (Table 5,
stage 2). However, both instruments were very weak pre-
dictors of the exposure, explaining only 2.6% and 0.4%
of the variance, respectively (Table 5, stage 1). In addition,
the IV approach was inefficient because of the relatively
small sample size (i.e., only 7,252 subjects were exposed
to conventional antipsychotic medications), resulting in
wide confidence intervals. This problem was further com-
pounded by the use of weak instruments that yielded highly
variable estimates of exposure effects.
Figure 2 displays the strengths of the association (odds ratio
(OR)) between exposure and a potential unmeasured con-
founder (OREC) and the association (relative risk (RR)) be-
tween confounder and outcome (RRCO) that would be required
to fully explain the observed increased mortality associated
with conventional antipsychotic medication use (hdPS-
adjusted relative risk ¼ 1.34) if in truth no such increase ex-
isted. For an unmeasured confounder present in 25% of the
population, relative risks of 3 or more linking the hypothet-
ical confounder to both conventional antipsychotic medica-
tion use and mortality would be needed to fully explain the
observed association. For confounders present in 5% or 1% of
the population, relative risks greater than 4.5 and 9, respec-
tively, would be needed. For an apparent association of 1.28
(lower bound of the 95% confidence interval for the hdPS-
Table 4. Risk of Death Among Nursing Home Residents Within 180 Days After Initiation of Antipsychotic Medication Use (Conventional vs.
Atypical), As Determined By Propensity Score Analyses, With and Without Adjustment for Clinical (MDS) and Nursing Home (OSCAR)
Information, United States, 2001–2005
Model






95% CI RR 95% CI RR 95% CI
PS decilea
Claims only 8.17 7.00, 9.34 7.07 5.89, 8.24 1.39 1.33, 1.45 1.34 1.28, 1.40
Claims þ MDS 7.87 6.70, 9.04 7.00 5.83, 8.17 1.37 1.32, 1.43 1.34 1.28, 1.40
Claims þ OSCAR 8.37 7.20, 9.55 7.07 5.89, 8.24 1.40 1.34, 1.46 1.34 1.28, 1.40
Claims þ MDS/OSCAR 7.79 6.61, 8.96 7.00 5.83, 8.17 1.36 1.31, 1.42 1.34 1.28, 1.40
Matching 1:1b
Claims 8.50 7.05, 9.94 7.06 5.60, 8.53 1.39 1.32, 1.47 1.31 1.24, 1.38
Claims þ MDS 7.59 6.15, 9.02 7.00 5.53, 8.46 1.34 1.27, 1.41 1.30 1.23, 1.38
Claims þ OSCAR 8.10 6.64, 9.55 7.06 5.60, 8.53 1.37 1.29, 1.45 1.31 1.24, 1.38






95% CI RRc 95% CI RRc 95% CI
PS decile
Claims only 24.45 20.87, 28.04 20.86 17.34, 24.38 1.52 1.44, 1.60 1.45 1.37, 1.53
Claims þ MDS/OSCAR 23.41 19.82, 27.00 20.60 17.09, 24.11 1.49 1.41, 1.57 1.45 1.37, 1.52
Abbreviations: CI, confidence interval; hdPS, high-dimensional propensity score; MDS, MinimumData Set; OSCAR, Online Survey, Certification
and Reporting; PS, propensity score; RR, risk ratio.
a n ¼ 77,912 after truncation of 2.5% of subjects on either side of the PS distribution.
b 99% of users of conventional antipsychotic medication and 10% of users of atypical antipsychotic medication were matched.
c Censoring at the time of death or 180 days, whichever came first.
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adjusted analysis), the required strength would be greater
than 2.5 for an unmeasured confounder present in, at most,
25% of the population.
DISCUSSION
In this study of 82,012 older patients initiating use of
antipsychotic medication after admission to a nursing home,
those for whom conventional agents were prescribed had a
34% higher risk of death in the short term than those for
whom atypical agents were prescribed, which corresponds to
an additional 7.0 deaths per 100 patients treated with conven-
tional agents. This finding of an increased risk with conven-
tional antipsychotic agents versus atypical agents is consistent
with findings from earlier studies in both predominantly
community-dwelling cohorts (12–14) and long-term-care
cohorts (13).
Nonrandomized studies using health-care utilization data
are particularly scrutinized for their limited control of con-
founders and their potential for misclassifying diagnoses (16).
In this study context, concern has been raised that patients who



































Increasing levels of adjustment
Figure 1. Risk of death among nursing home residents within 180 days of the start of antipsychotic medication use (conventional vs. atypical)
according to different analytic approaches representing increasing levels of adjustment. For ease of interpretation, the y-axis does not start at
the null value. (MDS, Minimum Data Set; OSCAR, Online Survey, Certification and Reporting; PS, propensity score; hdPS, high-dimensional
propensity score).
Table 5. Risk of Death Among Nursing Home Residents Within 180 Days After Initiation of Antipsychotic Medication Use (Conventional vs.
Atypical), As Determined By Instrumental-Variable Estimationa, United States, 2001–2005
Unadjusted Adjustedb
RD 95% CI Partial R 2 RD 95% CI Partial R 2
Stage 1: IV strength
IV1: 0 vs. >33% conventional antipsychotic 0.145 0.122, 0.168 0.026 0.138 0.116, 0.161 0.024
IV2: prior patient 0.063 0.053, 0.072 0.004 0.058 0.049, 0.066 0.004
Stage 2: effect estimate
IV1: 0 vs. >33% conventional antipsychotic 10.55 0.08, 21.18 8.84 1.28, 18.95c
IV2: prior patient 9.54 7.03, 26.10 8.59 8.97, 26.14c
Abbreviations: CI, confidence interval; IV, instrumental variable; RD, risk difference.
a IV1: n ¼ 36,153; IV2: n ¼ 74,723.
b Adjusted for sex, race, calendar year, dementia treatment, and prior use of antidepressant, hypnotic, or other psychotropic medications.
c Standard errors were not calculated robustly because of problems with model convergence.
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to be prescribed a conventional antipsychotic agent than an
atypical agent, resulting in overestimation of the association
(18). However, an earlier study that assessed residual con-
founding using survey data found that correction for 5 factors
that are unmeasured in claims data (i.e., body mass index,
smoking, Activities of Daily Living score, cognitive impair-
ment, and physical impairment) resulted in a stronger asso-
ciation rather than a weaker association (35).
Our study population consisted of patients eligible for
Medicaid. While this might have affected the rate of usage
of the cheaper conventional antipsychotic medications, this
restriction should not have affected the validity of our find-
ings, since the central issue determining internal validity is
comparability between the subcohorts included. As long as
socioeconomic status and its correlates do not modify the
association between antipsychotic medication and short-term
mortality, the findings should also be generalizable (i.e.,
externally valid) (36).
Confounder information derived from health-care utiliza-
tion or claims data was supplemented with clinical assessment
data as recorded in the MDS. The MDS, which is part of the
US federally mandated process for clinical assessment of all
residents in Medicare- or Medicaid-certified nursing homes,
provides a comprehensive assessment of each resident’s func-
tional capabilities and helps nursing home staff identify
health problems. The data are reported by the nursing homes
themselves and are reviewed by nursing home inspectors but
are not formally checked to ensure accuracy, yet most elements
of the MDS have been shown to demonstrate good reliability
(37, 38). As potential confounders of the association between
antipsychotic medication and all-cause mortality, MDS
markers of ill health, such as severity of physical and cog-
nitive impairment, were of particular interest in this study. In
addition, it has been suggested that nursing home patients
may be at increased risk of death simply by being admitted to
a facility with poor quality indicators, such as a higher intensity
of antipsychotic medication use (39). We accounted for poten-
tial nursing home quality indicators through use of the OSCAR
database, which reflects the findings from state inspections
and complaint investigations. Adjustment for these measured
clinical and nursing home characteristics, however, did not
meaningfully affect the effect estimates.
We used hdPS techniques in an effort to mitigate residual
confounding by unobserved factors. The assumption under-
lying this approach is that health-care utilization or claims
data can be viewed as a set of proxies that indirectly describe
the health status of patients through the lenses of health-care
providers and coders operating under the constraints of a
specific health-care system. By measuring a large battery of
proxy variables, this approach aims to increase the likelihood
that in combination they serve as a good proxy for relevant
unobserved confounding factors (30).
In contrast to ‘‘kitchen sink’’ models, which indiscrimin-
ately include covariates in a PS model, the hdPS algorithm
implements current knowledge regarding appropriate variable
selection for PS models (e.g., variables are selected on the
basis of their potential for confounding, and potential instru-
ments are removed after review of the univariate associations
Figure 2. Example of sensitivity analysis of residual confounding (rule-out approach) for an estimated relative risk (RR) of 1.34 and different levels
of confounder prevalence (open circle: prevalence of confounder (Pc) ¼ 0.25; filled square: Pc ¼ 0.05; filled circle: Pc ¼ 0.01). Each line splits the
area into two. The upper right area represents all combinations of an association (odds ratio (OR)) between exposure and confounder (OREC) and
an association between confounder and outcome (RRCO) that would create confounding by an unmeasured factor strong enough to move the point
estimate of RR to the null value (RR¼ 1) or beyond. The area to the lower left represents all parameter combinations that would not be able to move
the estimated RR toward the null.
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between the selected variables and the exposure and outcome)
(25, 30). In addition, by considering a multitude of variables
addressing the same construct of a confounding factor, the
hdPS approach also reduces the potential impact on confound-
ing adjustment of ‘‘missing’’ claims data, that is, those that
were not observed by the physician or not recorded by the
system. Since it has been found that inclusion of interactions
leaves the hdPS-adjusted effect estimates largely unchanged
(30), we did not include them in our models. By design, all
empirical covariates are categorical, and therefore nonlin-
earity is not a concern when implementing the algorithm.
In some typical pharmacoepidemiologic studies of treat-
ment effects, proxy adjustment via hdPS generated effect
estimates closer to randomized trial findings than standard
covariate adjustment of investigator-predefined variables (30).
In our study, use of hdPS changed the absolute effect from
7.79 fewer deaths per 100 persons over 180 days to 7.00 per
100 persons and the relative effect from 1.36 to 1.34. Although
we have no gold standard against which to evaluate our results,
the monotonic trend of a reduction in effect size with increas-
ing levels of adjustment (see Figure 1) hints at improved
confounding control with each level of adjustment. These
findings suggest that there may be some confounding caused
by clinical characteristics other than the measures reported
in the MDS. Alternatively, the MDS variables may have been
reported with sufficient nondifferential misclassification to
limit the ability to control fully for the confounding.
IVestimation, which by design can control for unmeasured
patient characteristics, appeared to confirm the findings of
an increased mortality risk with conventional antipsychotic
agents, but the instruments were too weak to permit inter-
pretation of the estimated risk differences (40).
The sensitivity analyses demonstrated that very strong mor-
tality risk factors that are fairly imbalanced among exposure
groups must be unmeasured and uncontrolled in our study to
explain the observed association. The results have already
been adjusted for most known, strong, independent mortality
risk factors, and any unmeasured confounder of the required
strength would also have to be independent of the confounders
we adjusted for; that is, correlated confounders such as patient
vulnerability are to some extent adjusted by factors like cog-
nitive and functional impairment and awake time. Although
it is unlikely that we missed such a strong single confounder,
it is conceivable that several weaker confounders may have
acted together and explain the apparent effect.
In summary, findings from nonrandomized studies assessing
the safety of conventional antipsychotic agents versus atypical
antipsychotic agents have been criticized for being caused
by residual confounding by unmeasured factors channeling
the prescribing of conventional agents to patients at higher
risk of death. Use of different analytic techniques to mitigate
the effects of confounding by measured factors and, to a lesser
degree, unmeasured factors consistently decreased but did not
eliminate the observed association in a population of nursing
home patients. In this study, the addition of clinical charac-
teristics indicative of frailty and typically not available in
administrative claims data did not meaningfully affect the
effect estimates.
While confirmation of these findings in other empirical
examples is in order, our results suggest that hdPS adjustment
based on claims data—which, in contrast to conventional
confounder adjustment methods, does not rely on a limited
number of investigator-specified covariates but taps into layers
of information that investigators have until recently not
exploited—may provide more valid estimates than conven-
tional approaches using claims data enriched with clinical
information, often believed to include important confounding
variables. Given that plausible IVs have been difficult to find
in epidemiology and medicine (including in this study) (31),
the hdPS approach may offer a promising and practical alter-
native to enhance the causal interpretation of effect estimates
when residual confounding by indication is a concern.
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